Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6701869 | 0.88 | CDK1 (0.56) | CDK1CCNB1CA2CA9MEN1 | |
| SCHEMBL875991 | 0.87 | CDK1 (0.66) | CDK1CCNB1CA2CA9MEN1 | |
| SCHEMBL460228 | 0.86 | CDK1 (0.66) | CDK1CCNB1CA2CA9MEN1 | |
| SCHEMBL8619982 | 0.84 | CDK1 (0.57) | CDK1CCNB1CA2CA9MEN1 | |
| SCHEMBL9300815 | 0.83 | CDK1 (0.60) | CDK1CCNB1CA2CA9MEN1 | |
| SCHEMBL925520 | 0.82 | CDK1 (0.63) | CDK1CCNB1CA2CA9MEN1 | |
| SCHEMBL55938 | 0.82 | CDK1 (0.57) | CDK1CCNB1CA2CA9MEN1 | |
| SCHEMBL20511784 | 0.82 | CDK1 (0.57) | CDK1CCNB1CA2CA9MEN1 | |
| SCHEMBL4317794 | 0.82 | CDK1 (0.57) | CDK1CCNB1CA2CA9MEN1 | |
| SCHEMBL346869 | 0.81 | CDK1 (0.76) | CDK1CCNB1CA2CA9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524510-B2 | Alkyl-glycoside enhanced vaccination | THE UAB RESEARCH FOUNDATION (US) | 2009-04-28 | — | — | US | claimed |
| EP-1863511-A2 | ALKYL-GLYCOSIDE ENHANCED VACCINATION | UAB Research Foundation (US) | 2007-12-12 | — | — | EP | claimed |
| US-20060233761-A1 | Noninvasive immunization; immunostimulants | UAB RESEARCH FOUNDATION, THE | 2006-10-19 | — | — | US | claimed |
| WO-2006091722-A2 | ALKYL-GLYCOSIDE ENHANCED VACCINATION | UAB RESEARCH FOUNDATION (US) | 2006-08-31 | — | — | WO | claimed |
| US-20240197719-A1 | FORMULATIONS AND METHODS FOR THE PREVENTION OF OPIOID OVERDOSE | AEGIS THERAPEUTICS, LLC (US) | 2024-06-20 | — | — | US | disclosed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| EP-3328898-B1 | TRKB OR TRKC AGONIST COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC CONDITIONS | OTONOMY INC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-11918655-B2 | Intranasal epinephrine formulations and methods for the treatment of disease | AEGIS THERAPEUTICS, LLC (US) | 2024-03-05 | — | — | US | disclosed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| US-20240066028-A1 | COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2024-02-29 | — | — | US | disclosed |
| US-20240041983-A1 | IMPROVED PHARMACEUTICAL FORMULATIONS OF GLP-1 RECEPTOR AGONISTS | CYPRUMED GMBH (AT) | 2024-02-08 | — | — | US | disclosed |
| US-20240024485-A1 | INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE | NEF ROYALTY SUB LLC | 2024-01-25 | — | — | US | disclosed |
| US-20060045868-A1 | Absorption enhancers for drug administration | AEGIS THERAPEUTICS LLC | 2006-03-02 | — | — | US | disclosed |
| US-20060046962-A1 | Absorption enhancers for drug administration | AEGIS THERAPEUTICS LLC (US) | 2006-03-02 | — | — | US | disclosed |
| US-20060046969-A1 | Antibacterial compositions for drug administration | AEGIS THERAPEUTICS LLC (US) | 2006-03-02 | — | — | US | disclosed |
| US-20060045869-A1 | Absorption enhancers for drug administration | AEGIS THERAPEUTICS LLC | 2006-03-02 | — | — | US | disclosed |
| US-5817634-A | Methods of treating diabetes mellitus and clycogen storage disease | THE UAB RESEARCH FOUNDATION (US) | 1998-10-06 | — | — | US | disclosed |
| US-5661130-A | NONTOXIC, NONIONIC ALKYL GLYCOSIDE HAVING A HYDROPHOBIC ALKYL JOINED BY A LINKAGE TO A HYDROPHILIC SACCHARIDE | THE UAB RESEARCH FOUNDATION (US) | 1997-08-26 | — | — | US | disclosed |
| US-5384128-A | Method of and compounds for treatment for cystic fibrosis | UNIVERSITY OF ALABAMA RESEARCH FOUNDATION (US) | 1995-01-24 | — | — | US | disclosed |
| WO-1995000151-A1 | ABSORPTION ENHANCERS FOR DRUG ADMINISTRATION | UAB RESEARCH FOUNDATION (US) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918655-B2 | Intranasal epinephrine formulations and methods for the treatment of disease | ADRA2C, ADRA2A, ADRB2 | CDK1 4857/4885CCNB1 4816/4885CA2 4062/4885 |
| US-20240041983-A1 | IMPROVED PHARMACEUTICAL FORMULATIONS OF GLP-1 RECEPTOR AGONISTS | GLP1R, GIPR, GCGR | CDK1 3104/4885CCNB1 3292/4885CA2 1526/4885 |
| US-20240066028-A1 | COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS | CALCB, CALCA, CALCRL | CDK1 4084/4885CCNB1 2905/4885CA2 2407/4885 |
| US-20240197719-A1 | FORMULATIONS AND METHODS FOR THE PREVENTION OF OPIOID OVERDOSE | OPRK1, OPRM1, OGFR | CDK1 4496/4885CCNB1 4624/4885CA2 4303/4885 |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | CDK1 4878/4885CCNB1 4692/4885CA2 4522/4885 |
| US-20240024485-A1 | INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE | ADRA2C, ADRA2A, ADRB2 | CDK1 4857/4885CCNB1 4816/4885CA2 4062/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | CDK1 3532/4885CCNB1 4200/4885CA2 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.